NanoViricides Reports Q4 2024 Financials and NV-387 Clinical Trials Progress

NanoViricides, Inc. has filed its Quarterly Report for the quarter ending December 31, 2024. The company reports $3.96 million in cash and $7.17 million in net property and equipment, with liabilities at approximately $1.18 million. Despite raising $4 million, the funding available through liabilities remains insufficient for operations planned until early 2026.

Focus is on advancing NV-387, a broad-spectrum antiviral, to Phase II clinical trials for MPox infection in Central Africa. NV-387 has shown promise in treating various viruses, with favorable Phase I results. Clinical trial sites in two African countries have been prepared for MPox, an infection with higher fatality rates than COVID.

NanoViricides is also readying NV-387 against a potential Bird Flu pandemic, highlighting its broad-spectrum capabilities. The company stresses the impending need for advanced antivirals beyond conventional options. Additionally, regulatory advancements are planned for NV-387 in treating Viral Acute Respiratory Infections.